William Carson, MD

Frmr CEO & Chairman of the Board, Otsuka Pharmaceutical

A psychiatrist by training, Dr. Bill Carson has a wealth of knowledge around regulatory compliance and working through FDA approvals having successfully brought a number of mainstream drugs to market, including Abilify, which returned multiple billions of dollars for the six months gained at the end of the Abilify patent for obtaining pediatric exclusivity. Also under his leadership Otsuka was able to launch the Abilify follow-on, Rexulti, Jynarque for polycystic kidney disease, and ultimately the first FDA-approved digital medicine, Abilify MyCite.

Investments & Boards
Incubated